Need professional-grade analysis? Visit stockanalysis.com
$271.97M
N/A
N/A
N/A
Price Chart
Risk-Adjusted Performance
SAB Biotherapeutics Inc (SABS) Price Performance
SAB Biotherapeutics Inc (SABS) trades on United States in USD. The company is classified in the Healthcare sector under the Biological Products industry. The stock currently trades at $3.87, up 3.20% from the previous close.
Over the past year, SABS has traded between a low of $1.11 and a high of $4.58. The stock has gained 152.9% over this period. It is currently 15.5% below its 52-week high.
SAB Biotherapeutics Inc has a market capitalization of $271.97M.
About SAB Biotherapeutics Inc
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
Company Info
- Sector
- Healthcare
- Industry
- Biological Products
- Exchange
- United States
- Currency
- USD
- Country
- United States
Financial Metrics
- Revenue (TTM)
- $1.32M
- EBITDA
- $-45,871,776
- Profit Margin
- -2579.03%
- EPS (TTM)
- -0.79
- Book Value
- 3.18
Technical Indicators
- 52 Week High
- $6.60
- 52 Week Low
- $1.00
- 50 Day MA
- $3.99
- 200 Day MA
- $2.96
- Beta
- 0.61
Valuation
- Trailing P/E
- N/A
- Forward P/E
- -11.73
- Price/Sales
- 205.66
- Price/Book
- 1.22
- Enterprise Value
- $106.54M